ReDirection: Self help program based on principles for cognitive behavioral therapy
Study summary
The overall aim of the study is to evaluate the effectiveness of the ReDirection program for individuals with low or medium risk to commit child sexual abuse.
Primary question: Is ReDirection a feasible, effective, and safe method in reducing low to medium risk participants' use of CSAM and related behaviors?
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Sufficient language skills: English, Swedish, Finnish, Czech, Slovak, German, or Spanish
* concern about sexual interest regarding children\*,
* CSAM use past six month
* Low to medium risk for committing child sexual abuse according to the SChiMRA scale
Exclusion Criteria:
\- Participants with a severe psychiatric illness (such as high acute suicide risk or severe substance abuse) will be excluded, or lack of serious intentions to participate.
Primary outcome measure(s)
Sexual interest involving children — Pre-intervention, during the intervention, and immediately after the intervention. Measured by Sexual Symptom Assessment Scale (SASS)(0-48 points; higher scores indicate more interest).
Child sexual abuse material usage — Pre-intervention, during the intervention, and immediately after the intervention. Measured with Sexual Child Molestation Risk Assessment (SChiMRA+), part B, item 1 (self-reported time spent last week in hours watching CSAM) including 3 follow up questions (about time/day, severity, and of youngest child).
Other behaviors related to sexual interest in children. — Pre-intervention, during the intervention, and immediately after the intervention. Time spent last week (hours), as self reported on the SChiMRA+ scale part B, item 4.
Depressive symtoms — Pre-intervention, and immediately after the intervention. Scores on the PHQ-9 questionnaire (Patient Health Questionnaire; 0-27 points; higher scores indicate more severe depressive symptoms).
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.